Markets:

Overview

News

Currencies

International

Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

31.67 +0.38 (+1.21%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Rapport Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Via The Motley Fool

Topics Regulatory Compliance

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.

Via The Motley Fool

Topics Regulatory Compliance

Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened ↗

September 08, 2025

Via Stocktwits

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗

March 16, 2026

Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.

Via The Motley Fool

Topics Regulatory Compliance

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Via The Motley Fool

Topics Regulatory Compliance

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

November 19, 2025

Via Benzinga

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Q3 2025 Earnings Beat and Positive Phase 2a Seizure Data ↗

November 06, 2025

Rapport Therapeutics beats Q3 earnings estimates, reports strong Phase 2a data for its lead drug candidate RAP-219, and has cash into 2029.

Via Chartmill

Topics Earnings

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 10, 2025

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

September 09, 2025

Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Top movers analysis one hour before the close of the markets on 2025-09-08: top gainers and losers in today's session. ↗

September 08, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 08, 2025

Via Benzinga

Top stock movements in today's session. ↗

September 08, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Gold Moves Higher; Robinhood Shares Jump ↗

September 08, 2025

Via Benzinga

Rapport Therapeutics, Planet Labs, QuantumScape, EchoStar And Other Big Stocks Moving Higher On Monday ↗

September 08, 2025

Via Benzinga

Nasdaq Surges 150 Points; Planet Labs Shares Jump After Q2 Results ↗

September 08, 2025

Via Benzinga

Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures ↗

September 08, 2025

The company is working on a treatment for a form of epilepsy that tends to be difficult to control.

Via Investor's Business Daily

Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year ↗

September 08, 2025

Rapport Therapeutics' RAP-219 cut seizures significantly in a Phase 2a trial, with strong results and a favorable safety profile driving next steps.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 08, 2025

Via Benzinga

Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗

September 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 05, 2025

Via Benzinga

Friday's after hours session: top gainers and losers ↗

September 05, 2025

After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Phibro Animal Health, Pure Storage, Snowflake, Build-A-Bear Workshop And Other Big Stocks Moving Higher On Thursday ↗

August 28, 2025

Via Benzinga

Rapport (RAPP) Q2 Net Loss Widens 47% ↗

August 07, 2025

Via The Motley Fool

Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Narrower-Than-Expected Q2 2025 Loss Amid Clinical Progress ↗

August 07, 2025

Rapport Therapeutics reports Q2 2025 net loss of $26.7M ($0.75/share), beating estimates. Focus remains on Phase 2a trial for RAP-219 in epilepsy, with results expected in September. Cash reserves...

Via Chartmill

This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

August 06, 2025

Via Benzinga

ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 28, 2025

Via Benzinga

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

June 12, 2025

Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.

Via MarketBeat

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.